ArticleJournal of cellular physiology2017

A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

Teresa Gamucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.